Glevo

Glevo – drug with antimicrobic bactericidal action.

Form of release and structure

Glevo is let out in the form of tablets, film coated: round, biconvex, brick-red (on 250 mg) or light orange with a pink shade (on 500 mg) colors, with the line of a break from one of the parties (on 5 pieces in blisters, on 1, 2 or 5 blisters in a cardboard pack).

Is a part of 1 tablet:

• Active agent: levofloxacin (in the form of a gemigidrat) – 250 or 500 mg;
• Auxiliary components: кросповидон, microcrystallic cellulose, povidone (K-30), starch, magnesium stearate, microcrystallic cellulose (avitset pn101).

Structure of a film cover: a macrogoal (polyethyleneglycol 6000), dye ferrous oxide red, a gipromelloza, dibutyl phthalate, titanium dioxide, talc, dye ferrous oxide yellow (tablets on 500 mg).

Indications to use

Glevo is appointed for treatment of the infectious and inflammatory diseases caused by microorganisms, sensitive to active agent of drug, the following systems and bodies:

• ENT organs (including acute sinusitis);
• The urinary system and kidneys (complicated and uncomplicated infections, including prostatitis, acute pyelonephritis);
• Lower parts of respiratory tracts (including community-acquired pneumonia, exacerbation of chronic bronchitis);
• Soft tissues and skin (abscess, the suppurated atheromas, furunkuleza);
• Generative organs;
• Abdominal cavity (along with other medicines having effect on anaerobic microflora).

Contraindications

• Epilepsy;
• Damage of sinews at earlier carried out treatment of a hinolonama;
• Pregnancy and period of a lactation (breastfeeding);
• Age (up to 18 years);
• Hypersensitivity to drug components, and also to other ftorkhinolona.

Glevo should appoint with care the patient of advanced age (because of high risk of the accompanying decrease in function of kidneys), and also at deficit glyukozo-6-fosfatdegidrogenazy.

Route of administration and dosage

Glevo is accepted inside by 1-2 times a day. Tablets need to be swallowed entirely, washing down them with enough liquid (100-250 ml). Drug can be accepted between meals or before food. It is not necessary to chew tablets.

Doses are defined by weight and the nature of an infection, and also sensitivity to Glevo's action of the estimated activator.

The following mode of dosing is recommended to patients with normal or moderately reduced function of kidneys (the clearance of creatinine is more than 50 ml in a minute):

• Sinusitis: once a day on 500 mg for 10-14 days;
• Exacerbation of chronic bronchitis: once a day on 250 or 500 mg for 7-10 days;
• Community-acquired pneumonia: 1-2 times a day on 500 mg for 7-14 days;
• Uncomplicated infections of urinary tract: once a day on 250 mg for 3 days;
• Prostatitis: once a day on 500 mg for 28 days;
• The complicated infections of urinary tract, including pyelonephritis: once a day on 250 mg for 7-10 days;
• Infections of soft tissues and skin: 1-2 times a day on 250 or 500 mg for 7-14 days;
• Infections of an abdominal cavity: once a day on 500 mg for 7-14 days (along with the antibacterial medicines operating on anaerobic flora).

Patients with renal failures need correction of the mode of a drug dosing.

As well as during use of other antibiotic means, it is recommended to continue Glevo's therapy not less than 2-3 days after a reliable eradikation of the activator or after normalization of body temperature.

After the continuous out-patient peritoneal dialysis (COPPD) or a hemodialysis introduction of additional doses is not required.

For patients of advanced age the mode of dosing is not changed, except cases of low clearance of creatinine.

At functional disturbances of a liver special selection of doses is not required as active agent is metabolized in a liver in an insignificant measure.

If administration of drug was missed, it is necessary to take a pill as soon as possible. Further it is necessary to continue administration of drug according to the scheme.

Side effects

During therapy development of disturbances from some systems and bodies is possible:

• Cardiovascular system: lengthening of an interval of QT, vascular collapse, lowering of arterial pressure, tachycardia; extremely seldom – a ciliary arrhythmia;
• Urinary system: acute renal failure, intersticial nephrite, giperkreatininemiya;
• Alimentary system: a loss of appetite, nausea, hepatitis, diarrhea (including with blood), digestion disturbance, vomiting, a pseudomembranous coloenteritis, an abdominal pain, a hyperbilirubinemia, increase in activity of hepatic transaminases, dysbacteriosis;
• Musculoskeletal system: tendinitis, muscular weakness, arthralgia, rupture of sinews, mialgiya, рабдомиолиз;
• Endocrine system: a hypoglycemia (the increased sweating, increase in appetite, nervousness, a shiver);
• Central and peripheral nervous system: dizziness, a headache, confusion of consciousness, weakness, sleeplessness, drowsiness, concern, a tremor, fear, paresthesias, motive frustration, hallucinations, a depression, epileptic seizures (at predisposed patients);
• System of a hemopoiesis: thrombocytopenia, neutropenia, hemolitic anemia, eosinophilia, leukopenia, pancytopenia, agranulocytosis, hemorrhages;
• Sense bodys: hearing disorder, sight, sense of smell, tactile and flavoring sensitivity;
• Allergic reactions: hyperemia and itch of skin, hypostasis of mucous membranes and skin, acute anaphylaxis, malignant exudative erythema (Stephens-Johnson's syndrome), small tortoiseshell, bronchospasm, allergic pneumonitis, suffocation, toxic epidermal necrolysis (Lyell's disease), vasculitis;
• Others: development of superinfection, adynamy, photosensitization, persistent fever, porphyria aggravation.

Special instructions

Patients during therapy need to carry out adequate hydration of an organism.

At development of symptoms of pseudomembranous colitis and a tendinitis it is necessary to cancel immediately treatment and to appoint the corresponding therapy.

To avoid damage of integuments (photosensitization) during treatment it is necessary to avoid artificial and solar UF-radiation.

At patients with damages of a brain in the anamnesis (a severe injury, a stroke) development of spasms is possible. The risk of development of hemolysis increases at insufficiency glyukozo-6-fosfatdegidrogenazy.

During therapy it is necessary to be careful at control of motor transport, and also when performing potentially dangerous works demanding high concentration of attention and bystry psychomotor reactions.

Medicinal interaction

At simultaneous use of Glevo with some medicines there can be undesirable effects:

• Non-steroidal anti-inflammatory drugs, theophylline: convulsive readiness increases;
• Cimetidinum and medicines blocking canalicular secretion: removal of a levofloksatsin is slowed down;
• Glucocorticosteroids: the risk of a rupture of sinews increases;
• Hypoglycemic drugs: development hyper - and a hypoglycemia is possible (strict control of level of glucose in blood is necessary).

Glevo's action lowers сукральфат, the drugs oppressing motility of intestines, antiacid medicines with the content of aluminum/magnesium and salt of iron (it is necessary to observe a break between administrations of drugs not less than 2 hours).

Terms and storage conditions

To store in protected from light, the place, dry, unavailable to children, at a temperature up to 25 °C.

Period of validity – 2 years.